Bonviva 3mg/3ml Injection (1s)

Bonviva 3 mg/3 mL Injection contains ibandronate, an intravenous bisphosphonate that reduces bone resorption. It is used under medical supervision for the treatment of postmenopausal osteoporosis and reduction of fracture risk.

• Manufacturer Name: Roche
• Drug Class: Bisphosphonate bone-resorption inhibitor
• Dosage Form: Intravenous Injection
• Storage: Store at 2–8°C and protect from light. Do not freeze. Keep out of the reach of children.
• Pack Size: Pack of 1 Injection

• Ibandronate 3 mg per 3 mL injection

• Treatment of postmenopausal osteoporosis
• Reduction of the risk of vertebral fractures in appropriate patients
• Helps reduce excessive bone breakdown and maintain bone mineral density

For Adult

• The usual adult dose for postmenopausal osteoporosis is 3 mg administered intravenously once every 3 months.
• The injection should be administered by a qualified healthcare professional, usually over approximately 15–30 seconds.
• Calcium and vitamin D supplementation may be recommended when dietary intake is inadequate.
• Serum calcium, vitamin D status, and kidney function should be assessed before administration.

For Children

• Not recommended for use in children or adolescents.
• Pediatric safety and effectiveness have not been established.
• No pediatric weight-based dosage is established.

Side Effects

• Common effects may include back pain, muscle or joint pain, headache, dizziness, fatigue, nausea, or flu-like symptoms.
• Transient fever, chills, or injection-related reactions may occur after administration.
• Low blood calcium may cause muscle cramps, tingling, numbness, or spasms.
• Serious effects may include kidney function deterioration, severe allergic reactions, osteonecrosis of the jaw, or atypical femoral fracture.
• Seek urgent medical attention for facial swelling, breathing difficulty, severe muscle spasms, persistent thigh or groin pain, or jaw pain or delayed healing.

Contraindications

• Known hypersensitivity to ibandronate or any component of the injection
• Uncorrected hypocalcemia or other untreated mineral-bone disorders
• Severe renal impairment, particularly creatinine clearance below 30 mL/min, unless specifically directed by a specialist
• Use during pregnancy is generally avoided unless a specialist determines that treatment is essential
• Use with caution in patients with dental disease, planned invasive dental procedures, or a history of osteonecrosis of the jaw
• Patients should be medically assessed before treatment if they have swallowing, calcium, vitamin D, or kidney problems

Precautions & Warnings

• Other bisphosphonates or medicines that lower blood calcium may increase the risk of hypocalcemia.
• Calcium, magnesium, iron, and aluminum-containing supplements or antacids mainly affect oral ibandronate absorption and are not expected to significantly reduce the effect of intravenous administration.
• Concurrent nephrotoxic medicines, including some nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics, or certain cancer treatments, may increase kidney-related risk.
• Inform the healthcare professional about all medicines, supplements, and treatments before receiving the injection.
• No specific food interaction is expected with the intravenous formulation.

• Not generally recommended during pregnancy because bisphosphonates may cross the placenta and fetal safety is not established.
• Women who are pregnant, planning pregnancy, or who may be pregnant should consult a doctor before treatment.
• Breastfeeding safety is not well established; an alternative treatment may be preferred, particularly while nursing a newborn or premature infant.

Bonviva 3mg 3ml Injection Available Online in Pakistan

Dwatson offers Bonviva 3mg 3ml Injection at Rs.11500, with fast, discreet delivery across Pakistan.